Plain-English translation of NCT06042725 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called in combination with one or two standard multiple myeloma drugs to see which combinations work best and are safest. Researchers want to find the right dose of that can be paired with existing treatments for patients with a specific genetic type of multiple myeloma called t(11;14). The study will track how well the treatment works and what side effects patients experience.
Multiple myeloma is a serious blood cancer, and many patients eventually stop responding to current treatments. This medication has shown promise in early research, and doctors want to learn if combining it with existing drugs could help patients who have already been treated or who are newly diagnosed.
You likely qualify if…
You likely don't qualify if…
You will take the new medication by mouth every day, combined with one or two other standard drugs taken on specific days of each month-long cycle. You will visit the clinic regularly for blood tests, imaging scans (like X-rays or CT scans), and a bone marrow biopsy during screening and follow-up. The treatment continues for up to about 9 months (36 cycles) unless your disease gets worse or side effects become too difficult—your doctor will monitor you closely throughout.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States